According to National Institute of Health, approximately 50 million population in the United States are suffering from autoimmune diseases. The diseases in estimated to be one of the top 10 cause of death in women under the age 65, and it is the second highest cause of chronic illness. Also, it is the top cause of morbidity in women in the United States. There are more than 80 clinically different type of autoimmune diseases identified till date. Abnormal immune responses of the innate immune system can cause autoimmune diseases, which can damage body tissues and lead to abnormal organ functions. Immunological complications due to physiological processes within the human body leads to autoimmune diseases.
|Unit||Value (USD Million)|
|Key Companies Profiled||Abbott Laboratories (United States), Active Biotech AB (Sweden), AstraZeneca plc (United Kingdom), GlaxoSmithKline plc (United Kingdom), Eli Lilly and Company (United States), Zydus Cadila (India), Autoimmune Technologies (United States) and Bristol-Myers Squibb (United States)|
This growth is primarily driven by High Cost of Autoimmune Drugs due to the initiatives taken by the Government to reduce the cost therapies of autoimmune disorders like rheumatoid arthritis, Increased prevalence of autoimmune diseases and Introduction of affordable Biosimilars and its advanced treatment option for patients with autoimmune disorders..
Globally, a noticeable market trend is evident Owing to a huge patient pool and developing healthcare technology is expected to propel the market growth rate. The Pharmaceuticals sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Abbott Laboratories (United States), Active Biotech AB (Sweden), AstraZeneca plc (United Kingdom), GlaxoSmithKline plc (United Kingdom), Eli Lilly and Company (United States), Zydus Cadila (India), Autoimmune Technologies (United States) and Bristol-Myers Squibb (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The market appears to be highly competitive due to the presence of many market players who are offering multiple treatment options for Autoimmune disease. Apart from the high cost of the drugs, the complex treatment of autoimmune diseases and a severe lack of effective diagnostic, these factors are challenging the market. The competitive environment is expected to increase due to the product extensions, new products, and new applications of the products and services provided.
Key Developments in the Market:
In November 2018, The Food and Drug Administration approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS.
In February 2019, Calliditas Therapeutics AB announced the Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Autoimmune hepatitis (AIH). This confirms the high unmet medical need and further encourages us to continue to explore orphan indications in which we could leverage our existing expertise.
Owing to a huge patient pool and developing healthcare technology is expected to propel the market growth rate.
Market Growth Drivers:
High Cost of Autoimmune Drugs due to the initiatives taken by the Government to reduce the cost therapies of autoimmune disorders like rheumatoid arthritis, Increased prevalence of autoimmune diseases and Introduction of affordable Biosimilars and its advanced treatment option for patients with autoimmune disorders.
Insurers are reluctant to provide reimbursement for the drugs for the treatment of autoimmune diseases due to lack of knowledge.
Patent expiry of the drugs used for autoimmune disease and poor healthcare system in underdeveloped countries and Despite the efforts made by the Government, autoimmune drugs remains expensive, this may hamper the market growth
Factors such as the targeted therapeutic mechanism of biologics and the high cost of autoimmune drugs will provide considerable growth opportunities to autoimmune drugs manufactures of this market
AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.
Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Autoimmune Drugs Market
- Analysis about New Entrants in Autoimmune Drugs Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators
Against this Challenging Backdrop, Autoimmune Drugs Study Sheds Light on
The Autoimmune Drugs Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Autoimmune Drugs industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
Where Autoimmune Drugs industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.